Top 5 Bank Stocks To Buy Right Now

In this article, we’ll compare and analyze the financial ratios of Citizens Financial Group (CFG) following their earnings reports for Q2.

We’ll also compare CFG to their peers including U.S. Bancorp (USB), SunTrust Banks, Inc. (STI), Huntington Bancshares Incorporated (HBAN), BB&T Corporation (BBT), M&T Bank (MTB), PNC Financial Services Group Inc. (PNC), Regions Financial Corporation (RF), and Fifth Third Bancorp (FITB).

Highlights from the earnings report:

Citizens Financial: Q2 EPS of $0.63 beats by $0.04. Revenue of $1.4B (+9.4% Y/Y) in line.

Here are the press release highlights:

Net income of $318 million, up 31% from $243 million in the second quarter 2016. Includes a $26-million impact related to impairments on aircraft lease assets which, in addition to provision expense of $70 million, resulted in total credit-related costs of $96 million. Net interest income growth of 2%, strength in mortgage banking fees, service charges and fees and capital markets fees. Net interest margin expansion to 2.97% and an efficiency ratio of 61.9%. Total revenue of $1.4 billion increased 1%. $9-million decrease in noninterest income, driven by $11 million of finance lease impairments recorded in other income. Average deposits increased $836 million or 1%. Average interest-earning assets increased $1.2 billion or 1%, driven by 1% loan growth. Declared a third quarter cash dividend of $0.18 per common share, an increase of $0.04 per share, or 29%. The dividend is payable on August 16, 2017, to shareholders of record at the close of business on August 2, 2017.

We believe we are turning the corner and emerging from our turnaround phase, having made strong strides in growing our balance sheet and customer base and building out our capabilities in both Consumer and Commercial.” – CEO Bruce Van Saun via press release.

Top 5 Bank Stocks To Buy Right Now: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.

    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.

    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.

    OncoMed is down 36.1% to $5.60 this afternoon.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

Top 5 Bank Stocks To Buy Right Now: Cardtronics, Inc.(CATM)

Advisors’ Opinion:

  • [By Timothy Green]

    Non-bank ATM operator Cardtronics (NASDAQ:CATM) slumped on Friday despite reporting fourth-quarter results that beat analyst estimates on all fronts. The culprit driving the decline may be the company’s 2017 guidance, which calls for a decline in adjusted EPS. At 2:30 p.m. EST, the stock was down about 10%.

Top 5 Bank Stocks To Buy Right Now: Gentex Corporation(GNTX)

Advisors’ Opinion:

  • [By Lisa Levin] Related TRST Earnings Scheduled For October 21, 2016 Major Accounting Changes Are Coming To The Financial Industry
    Related MORN One Of The World's Most Powerful Women, Fidelity Personal Investing President Kathleen Murphy, To Tell Her Story At The Benzinga Global Fintech Awards The 2017 Benzinga Global Fintech Awards Will Include An 'Unprecedented Group' Of Judges Morningstar Packs Conference Lineup For Financial Advisors (Investor’s Business Daily) Companies Reporting Before The Bell
    Rockwell Collins, Inc. (NYSE: COL) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.33 billion.
    General Electric Company (NYSE: GE) is expected to report quarterly earnings at $0.17 per share on revenue of $26.46 billion.
    Honeywell International Inc. (NYSE: HON) is estimated to report quarterly earnings at $1.60 per share on revenue of $9.32 billion.
    Interpublic Group of Companies Inc (NYSE: IPG) is expected to report quarterly earnings at $0.03 per share on revenue of $1.76 billion.
    Schlumberger Limited. (NYSE: SLB) is estimated to report quarterly earnings at $0.26 per share on revenue of $7.02 billion.
    SunTrust Banks, Inc. (NYSE: STI) is expected to report quarterly earnings at $0.83 per share on revenue of $2.21 billion.
    ManpowerGroup Inc. (NYSE: MAN) is projected to report quarterly earnings at $1.11 per share on revenue of $4.68 billion.
    Kansas City Southern (NYSE: KSU) is estimated to report quarterly earnings at $1.15 per share on revenue of $593.82 million.
    Stanley Black & Decker, Inc. (NYSE: SWK) is projected to report quarterly earnings at $1.19 per share on revenue of $2.74 billion.
    WABCO Holdings Inc. (NYSE: WBC) is estimated to report quarterly earnings at $1.44 per share on revenue of $721.89 million.

Top 5 Bank Stocks To Buy Right Now: Calavo Growers, Inc.(CVGW)

Advisors’ Opinion:

  • [By Lee Jackson]

    Calavo Growers Inc. (NASDAQ: CVGW) had the man at the top buying stock last week. CEO Lecil Cole purchased 95,000 shares of the avocados and other perishable foods distributor at prices between $55.44 and $56.92 a share. The total for the purchase was set at $5 million. The stock closed the day last Friday at $58.30, in a52-week range of$48.745 to $71.48. The consensus price target is set at $73.17.

  • [By Shanthi Rexaline]

    Agricultural Produce Companies

    Limoneira Company (NASDAQ: LMNR): -32.1 percent since 2011. Calavo Growers, Inc. (NASDAQ: CVGW): +168.2 percent since 2011.

    Agri-Input Companies — Seeds/ Fertilizers/Pesticides Manufacturers

Top 5 Bank Stocks To Buy Right Now: Teladoc, Inc.(TDOC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Teladoc Inc (NASDAQ: TDOC) was down, falling around 6 percent to $33.70. First Baird downgraded Teladoc from Outperform to Neutral.

    Commodities

  • [By Steve Symington, Rich Smith, and Keith Speights]

    But from an investor’s perspective, that raises the question: Are there other stocks that could offer similar returns?So we asked three top Motley Fool contributors to each pick a stock they believe hasNVIDIA-like return potential. Read on to see why they chose CalAmp (NASDAQ:CAMP), Kratos Defense & Security (NASDAQ:KTOS), and Teladoc (NYSE:TDOC).

Leave a Reply

Your email address will not be published.